皮质骨圈在椎弓根钉固定系统中支撑作用的生物力学评价

目的：了解脊椎椎弓根钉固定系统在人体皮质骨圈（allograft fusion cage,AFC)植入椎间隙前后对脊柱稳定性的影响。方法：在8具新鲜成年猪离体腰椎标上，以L2－3，L3－R，L4－5节段为实验对象，测试各节段在正常状态下（正常组）、椎间盘切除并Steffee钢板固定（内固定组）、椎间盘切除AFC植入Steffee钢板固定（AFC组）等三种种状态下的轴向压缩刚度。结果：（1）内固定组节段轴向压缩刚度为正常组的14．0％；（2）AFC组节段的轴向压缩刚度明显增加，达到了正常椎间的轴向压缩刚度；（3）在相同轴向压缩载荷作用下，AFC给椎弓根钉受力移位较内固定组明显减小。结论：脊椎椎弓根钉固定系统在AFC椎间植入后，对脊椎稳定性较无AFC植入显著增强，其受力移位明显减小，即可显著减少临床断钉。钢板折弯的机会。     

Elbow reconstruction after excision of proximal ulna tumors: Challenges and solutions

Most malignant bone tumors are treated with surgical excision, adhering to oncologic principles, followed by reconstruction to preserve form and function whenever feasible. Primary bone tumors around the elbow are rare accounting for <1% of all skeletal tumors. They pose a reconstructive challenge, due to the complex interplay between the osseous & capsulo-ligamentous structures which is essential for elbow stability and function. Tumors affecting the proximal ulna are rare and reconstruction of the defects following these tumors is extremely challenging. Various reconstruction options like arthrodesis, autogenous bone grafts, allografts, re-implantation of sterilized tumor bone, pseudoarthrosis, and endoprosthesis have been tried with variable success. However, due to lack of standardization and the rarity of the site, surgeons are often in a dilemma to choose the correct option. This can lead to suboptimal functional outcomes and long-term failures. In this article, we reviewed the published literature on proximal ulnar tumors and noted the pros and cons of various reconstructive procedures. We have also attempted to formulate reconstruction recommendations based on the level of resection of proximal ulna.     

冷冻同种异体骨段移植修复股骨近段大块骨缺损

为观察大块冷冻同种异体骨移植后免疫功能的改变及预后,对13例恶性骨肿瘤瘤段切除后的骨缺损10.8～19.4cm(平均为14.6cm),分别采用冻冷异体松质骨段移植的髋关节加压融合术(6例)和异体股骨近段半关节移植成形术(7例)修复.10例分别于术前4天及术后14和28天检测其空腹外周血各项免疫学指标,以及术后3、6、9、12、24、48个月进行99mSPECT骨扫描(5例)和X-线片检查(12例),以观察宿主的免疫反应和异体骨愈合情况.结果:①外周血T淋巴细胞亚群(OKT3+,OKT4+,OKT8+)及血清补体(C3,C4)和循环免疫复合物(CiC)手术前后比较无显著性差异(P>0.05).②99mTe SPECT骨扫描显示:术后3～6个月移植的异体骨两端及髓腔内同位素浓集明显低于正常,而异体骨两端所对应的自体骨端同位素浓集明显高于正常,此现象于植入后9个月开始减弱,可达数年.X线片显示:异体骨愈合率为92.3%(12/13),2例移植的异体松质骨段于术后4～6年完全成活替代.以上可见:①冻冷异体骨段移植后宿主的全身免疫机能改变不明显,其反应是以局部炎症为主的细胞免疫过程;②异体骨可做为修复大块骨缺损的良好材料.     

深低温冷冻大段同种异体骨移植修复四肢骨肿瘤切除后大段骨缺损

目的：分析大段同种异体骨移植在治疗四肢骨肿瘤切除后骨缺损中的疗效。方法：对30例四肢骨肿瘤．按Enneking分期原则确定切除范围，进行瘤段广泛切除，大段异体骨移植修复骨缺损，平均移植骨段13．6cm，并辅以坚强内固定，对高恶性骨肿瘤进行术前、后化疗。结果：随访4～53个月，治疗满意率为85％，主要并发症是感染、局部复发、肺转移死亡，其发生率为20％，保肢率为80％。结论：大段同种异体骨移植，在治疗四肢骨肿瘤切除后骨缺损方面是一种有效可行的方法。     

Potential lack of “standardized” processing techniques for production of allogeneic and xenogeneic bone blocks for application in humans

In the present study, the structure of two allogeneic and three xenogeneic bone blocks, which are used in dental and orthopedic surgery, were histologically analyzed. The ultimate goal was to assess whether the components postulated by the manufacturer can be identified after applying conventional histological and histochemical staining techniques. Three samples of each material, i.e. allogeneic material-1 and -2 as well as xenogeneic material-1, -2 and -3, were obtained commercially. After decalcification and standardized embedding processes, conventional histological staining was performed in order to detect inorganic matrix, cellular or organic matrix components. Allogeneic material-1 showed trabecular bone-like structures, which were free of cellular components as well as of organic matrix. The allogeneic material-2 showed trabecular bone structures, in which connective tissue and cellular remnants were embedded. Additionally, some connective tissue, which resembled fat-like tissue, was found within this material. The xenogeneic material-1 showed trabecular bone-like structures and contained organic components comparable to that demonstrated for the allogeneic material-2. The xenogeneic material-2 showed trabecular bone structures with single cells located in lacunae. The xenogeneic material-3 also showed trabecular structures. Neither cellular nor organic matrix components were found within this material. According to the data of the present study, the allogeneic material-1 and the xenogeneic material-3 were the only investigated materials for which the obtained histological data were in accordance with the manufactureŕs advertised information. The remaining three materials showed discrepancies—although the manufacturers of all five bone substitute materials stated that their blocks were free of organic/cellular remnants. These data are of great clinical and material science interest. It seems that even patented processing techniques are not always able to deliver reproducible materials. Although the manufacturers of all five bone blocks stated that their blocks were free of organic/cellular remnants, our histological analysis revealed that three out of five bone blocks did contain such remnants. Such specimens might be able to induce an immune response within the recipient.     

Unexpected Fabry Disease in a Renal Allograft Kidney: An Underrecognized Cause of Poor Allograft Function

Fabry disease is an X-linked recessive lysosomal storage disease caused by a deficiency of α-galactosidase A, with characteristic ultrastructural cytoplasmic myelin-like inclusions. Renal lesions are seen in male and variably in heterozygous female patients. One previous report has described Fabry disease involving a renal allograft from a deceased female donor with no history of Fabry disease. The authors describe another case, in which suspicion for Fabry disease was raised ultrastructurally. This serves as a reminder that proteinuria after renal transplantation may be due to donor-derived disease. Fabry disease is probably an underrecognized cause of graft dysfunction. This case provides further justification for ultrastructural examination of renal allograft biopsies.     

The impact of non-HLA antibodies on outcomes after lung transplantation and implications for therapeutic approaches

The role of donor-specific antibodies (DSA) to mismatched human leukocyte antigens (HLA) in lung allograft rejection has been recognized over the past 20 years. During this time, there has been growing experience and recognition of an important role for non-HLA antibodies in lung allograft rejection. Multiple self-antigens have been identified that elicit autoimmune responses including collagen V, K-α 1 tubulin, angiotensin type 1 receptor, and endothelin type A receptor, but it is likely that other antigens elicit similar responses. The paradigm for the pathogenesis of these autoimmune responses consists of exposure of sequestered self-antigens followed by loss of peripheral tolerance, which then promotes allograft rejection. Studies have focused mainly on the impact of autoimmune responses on the development of Bronchiolitis Obliterans Syndrome or its mouse model surrogate. However, there are emerging data that illustrate that non-HLA antibodies can induce acute antibody-mediated rejection (AMR) after lung transplantation. Treatment has focused on antibody-depletion protocols, but experience is limited to cohort studies and appropriate controlled trials have not been conducted. It is noteworthy that depletion of non-HLA antibodies has been associated with favorable clinical outcomes. Clearly, additional studies are needed to identify the optimal therapeutic approaches to non-HLA antibodies in clinical practice.